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Abstract
Background: DNA methylation plays important roles in gene regulation during both normal developmental and
disease states. In the past decade, a number of methods have been developed and applied to characterize the
genome-wide distribution of DNA methylation. Most of these methods endeavored to screen whole genome and
turned to be enormously costly and time consuming for studies of the complex mammalian genome. Thus, they
are not practical for researchers to study multiple clinical samples in biomarker research.
Results: Here, we display a novel strategy that relies on the selective capture of target regions by liquid
hybridization followed by bisulfite conversion and deep sequencing, which is referred to as liquid hybridization
capture-based bisulfite sequencing (LHC-BS). To estimate this method, we utilized about 2 μg of native genomic
DNA from YanHuang (YH) whole blood samples and a mature dendritic cell (mDC) line, respectively, to evaluate
their methylation statuses of target regions of exome. The results indicated that the LHC-BS system was able to
cover more than 97% of the exome regions and detect their methylation statuses with acceptable allele dropouts.
Most of the regions that couldn’t provide accurate methylation information were distributed in chromosomes 6
and Y because of multiple mapping to those regions. The accuracy of this strategy was evaluated by pair-wise
comparisons using the results from whole genome bisulfite sequencing and validated by bisulfite specific PCR
sequencing.
Conclusions: In the present study, we employed a liquid hybridisation capture system to enrich for exon regions
and then combined with bisulfite sequencing to examine the methylation statuses for the first time. This technique
is highly sensitive and flexible and can be applied to identify differentially methylated regions (DMRs) at specific
genomic locations of interest, such as regulatory elements or promoters.
Background
The methylation of cytosines at CpG dinucleotides is an
important regulatory modification in the somatic cells of
mammals and other vertebrates [1,2]. It plays a vital role
in regulating gene transcription during diverse biological
processes, including embryonic development, X-chro-
mosome inactivation, and the maintenance of pluripo-
tency and chromosome stability [3-8]. Aberrant DNA
methylation is associated with many common diseases.
Recent evidence has demonstrated that the epigenetic
silencing of tumour suppressor genes due to abnormal
DNA hypermethylation is involved in cancer develop-
ment and progression [8,9]. Due to its relative genomic
stability and well-established role in cancer pathogen-
esis, it is likely that DNA methylation is an important
biomarker for the diagnosis and prognosis of certain dis-
eases [10].
Understanding the exact role of DNA methylation in
normal developmental and disease states requires
knowledge of the distribution of methylation in the gen-
ome. Fortunately, reference genome assemblies and
massively parallel sequencing enable the high-resolution
genome-wide profiling of cytosine methylation. With
this profiling, it is possible to identify methylation
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epigenome-wide association studies.
There are three main types of strategies that are cur-
rently available for the high-resolution detection of
DNA methylation based on the next generation sequen-
cing platform. The first is whole genome bisulfite
sequencing (WGBS), in which sodium bisulfite is applied
to the genomic samples to convert all unmethylated
cytosines to uracils. The uracil is subsequently recog-
nized as thymine after PCR amplification [11,12]. This
technique is the gold standard for cytosine methylation
analysis in both CpG and non-CpG contexts because it
allows for methylation detection at a single-base resolu-
tion [11,12]. However, whole genome sequencing is
extremely time consuming and costly, especially when
used to screen complex genomes. For this reason, it is
impractical for the survey of multiple biological samples.
The second approach is based on the enrichment of
methylated DNA fragments such as MeDIP-seq [13,14]
and MBD-seq [15], which employ 5-methylcytosine-spe-
cific antibodies and methyl-binding domain proteins,
respectively, to precipitate methylated fractions from a
randomly sheared genomic DNA sample. Although
these two methods are able to enrich fragments contain-
ing 5-methylcytosine, they screen the whole genome
without representation and cannot determine the
methylation statuses of individual CpGs within the frag-
ments [13-18]. Even when combined with bisulfite con-
version, these methods were still hampered by the
enrichment bias that was caused by the CpGs densities
and methylation statuses of the DNA fragments [16].
The third approach includes reduced representation
bisulfite sequencing (RRBS) and bisulfite padlock probes
(BSPP) [19-21]. RRBS digests genomic DNA with a spe-
cific restriction enzyme followed by bisulfite conversion
and sequencing of the size-selected fractions [19,20].
This technique is able to cover multiple regions, includ-
ing CpG islands, promoters and enhancer elements, and
can yield data at a single-base resolution. It is a robust
and relatively low-cost method but is limited to profiling
the defined regions that correspond to the recognition
sites of certain restriction enzymes [17,18,20,22]. Theo-
retically, BSPPs could be applied to detect any genomic
region of interest by the design of specific probes. How-
ever, because they are involved in the hybridization of
bisulfite-converted genomic DNA, each probe can only
target a limited number of CpGs. This limitation ham-
pers the flexibility of the probe design and applicability
of this technology [21].
In the present study, we designed a novel strategy,
termed liquid hybridization capture-based bisulfite
sequencing (LHC-BS), which utilized biotinylated RNA
probes to capture target regions of native genomic DNA
by liquid hybridization platform and then followed by
sodium bisulfite treatment and next-generation sequen-
cing to survey the methylation statuses of specific geno-
mic regions. Exome capture sequencing is a widely used
technique to study diseases, and methylation status is
gaining recognition as an important topic [23]. Here, we
performed target (exome) capturing and parallel bisulfite
sequencing to test the reliability of our platform. To
validate the applicability of our approach, two types of
samples were used: the YanHuang peripheral blood
sample (YH) and a mature dendritic cell (mDC) line.
Our results demonstrated that the current LHC-BS
method was as effective as the bisulfite system in detect-
ing methylation statuses of the captured regions. The
technique provided the foundations for future high-
throughput examinations of the methylation statuses of
any genomic regions of interest.
Result
Overview of LHC-BS
The LHC-BS assay was based on a protocol that applied
predesigned biotinylated RNA probes to capture target
genomic regions of interest for further analysis. In the
current study, we used the Agilent SureSelect Human
All Exon Kit to enrich all human exons, which totalled
approximately 38 Mb. The capturing was achieved using
a liquid hybridization system that required only 2-3 μg
of genomic DNA for the library construction in contrast
with the 20 μg that is required for the array-based cap-
ture method [24,25]. To briefly summarize the experi-
mental procedures, 2-3 μg of genomic DNA were
randomly fragmented to mean sizes of approximately
250 bp. The manufacturer’s protocols were followed for
creating the blunt ends and for the dA additions to the
3’ends and the methylcytosines modified adapter liga-
tions. A total of 500 ng of each adapter-ligated library
(147 ng/μl) were denatured and hybridised with biotiny-
lated RNA probes at 65°C for 24 h. Then, Dynabeads
®
M-280 Streptavidin was used for the separation of target
fragments, after which the captured beads were washed
and the DNA fragments were eluted. After the frag-
ments were treated with sodium bisulfite, PCR amplifi-
cation was performed and the amplicons were
sequenced using the Illumina/HiSeq 2000 (Figure 1).
Data generation
LHC-BS was successful in achieving sufficient coverage
of the target regions based on a relatively small amount
of sequencing. In this study, 88 M and 132 M raw reads
were generated for the YH blood sample and mDC cell
line, respectively (Additional File 1 Table S1). Of these
reads, more than 75 M and 106 M reads were uniquely
mapped back to the reference genome, giving unique
map rates of 85.36% and 80.27%, respectively. On aver-
age, the depths of coverage were 58× and 63× for the
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than 97% of the target exons were covered by unique
reads in both samples. Of these, 90.21% and 89.16% of
the regions were covered by at least 10 reads for each
sample, respectively. Furthermore, 71.93% of the reads
were enriched in the target regions for the YH blood
sample, and 75.96% for the mDC cell line, thus indicat-
ing the high capture specificity of this assay for exome.
Because bisulfite conversion can result in allele drop-
outs at low DNA concentrations, we further evaluated
the potential rate of allele loss for the YH sample by
evaluating heterozygous SNPs (more than 2 alleles)
(unpublished). Totally, 7172 heterozygous alleles were
identified in the target regions with sequencing depths
of more than 10× in YH whole genome bisulfite sequen-
cing research, and 6992 of them were identified hetero-
zygous by the current designed method. These results
indicated that the rate of allele dropout was 2.5% (Addi-
tional File 1 Table S2). The heterozygosity of A/G, C/T,
G/A and C/T was not included in this analysis because
it was possible that they were generated during the
bisulfite conversion.
Accuracy of target exon capture
Based on the massive sequencing reads that were
uniquely mapped to the reference genome, we further
examined the read distribution across the whole gen-
ome. As indicated in Figures 2a and 2b, the reads were
distributed across all chromosomes, indicating the effi-
cient coverage of the target regions. The average
sequencing depth for each chromosome was over 30×
for the negative strands in both the YH and mDC sam-
ples. To estimate the accuracy of target capture, we ran-
domly isolated data from a specific region of the DIP2B
gene that is located on human chromosome 12 and
used the Integrative Genomics Viewer (IGV) to assess
the read distributions for both the YH and mDC sam-
ples. Using the IGV, we were able to determine that the
profiles of the reads from the target region followed
normal distributions, and most of them were enriched
in the gene region (Figure 2c). These results verified the
accuracy of this technique in the capture of target
regions. The read distribution across chromosome 12 is
presented in Additional File 2 Figure S1.
Accuracy of methylation estimation of target regions
To estimate the methylation statuses of the captured
exon regions and evaluate the efficacy of LHC-BS in
detecting genomic DNA methylation, methylation
levels were assessed based on the following equation
for one certain cytosine site: mC reads/(C reads +mC
reads)*100%. Considering that not all unmethylated
cytosines could be converted to thymine following the
bisulfite treatment and because it is believed that non-
CpG methylation is barely discernable in human
somatic cells [26], we estimated the conversion rate by
calculating the methylation levels of the non-CpG sites
and adjusted the methylation levels of the CpG sites
accordingly. We had previously performed WGBS on
both samples and obtained sufficient data to evaluate
the genomic methylation statuses (unpublished data),
and we were thus able to apply these data to estimate
the accuracies of the methylation measurements that
were obtained using the LHC-BS method. We isolated
WGBS reads that represented exon regions with at
least nine-fold depths of coverage and performed cor-
relation analyses with the LHC-BS reads from both
samples. A correlation coefficient of 0.907 was
obtained for the YH blood sample from the compari-
son of data of the two methods (Additional File 3
Figure S2 a). Similarly, a correlation coefficient of
0.925 was reached for the comparison with the mDC
cell line (Additional File 3 Figure S2 b). Such high con-
sistencies between the two sets of data that were gener-
ated by the two distinct methods are indicative of the
accuracy of LHC-BS because WGBS is considered to
be the gold standard for measuring methylation.
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Figure 1 Overview of the LHC-BS process.G e n o m i cD N Aw a s
fragmented, end-repaired and fitted with methylated adapters prior
to the liquid hybridization. It was then subjected to bisulfite
conversion and PCR amplification.
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Page 3 of 10Secondly, we addressed the methylation levels in all
gene regions of the YH blood sample and mDC cell
line. As indicated in Figure 3, the methylation levels
across the target gene regions were very similar between
the two samples, suggesting similarities between the two
cell types that are both primarily comprised of immuno-
cytes. Due to these parallels, we were able to examine
technological reproducibility to some extent; specifically,
the average methylation level of all CpGs in the genomic
regions around the TSSs was identified to be 3%, which
is consistent with the published results from the whole
genome bisulfite sequencing of YH peripheral blood
mononuclear cells [26].
To characterize the slight differences in the DNA
methylation profiles between the samples, we performed
pair-wise comparisons between the YH blood cells and
mDC cell line. As expected, the results revealed that
only 21 out of the 165637 targeted regions significantly
differed between the two samples (see Methods), indi-
cating highly similar DNA methylation profiles
corresponding with the whole exon regions. A Gene
Ontology (GO) analysis was employed to address the
molecular functions of the genes from the 21exon
regions that exhibited significantly different DNA
methylation patterns (Table 1).
Validation of DNA methylation by BS-PCR
Certain biases may be introduced during exome capture,
thus hampering the accuracy of LHC-BS. To confirm
the methylation events that were detected by LHC-BS,
BS-PCR was performed on four randomly chosen geno-
mic fragments. These fragments had low, moderate or
high methylation levels in both the YH blood sample
and mDC cell line, and there were 27 individual CpG
sites in total. Fisher’s tests were applied to verify statisti-
cal efficacy, and it was observed that none of the CpG
sites presented with significant differences in DNA
methylation levels when the LHC-BS and BS-PCR
results were compared (Additional File 1 Table S3). For
instance, a region that is located in the 5’UTR of the
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Page 4 of 10MOBP gene was identified by LHC-BS to have moderate
methylation levels of 9.80% and 22.37% in the mDC cell
line and YH blood sample, respectively. Similar results
were observed for the two samples following BS-PCR
(Figure 4a). In the other three verified regions,
sequences from the DSPP gene presented with nearly
undetectable methylation levels (Figure 4b), and the
WDR37 and DIP2B genes were shown to be heavily
methylated using both technologies (Figure 4c and 4d).
Thus, taking into account the random selection of the
DNA fragments for validation, we did not observe any
bias in the detection of methylation levels using LHC-
BS.
Discussion
Along with the completion of various genome sequen-
cing projects and more wide spread uses of high-
throughput sequencing technologies, many strategies
have been developed to assess DNA methylation that
require the enrichment of specific genomic regions of
interest. For example, microarray-based strategies uti-
lized bisulfite-converted DNA to probe defined regions
by the bimodal hybridization of either unconverted or
converted probes [24]. This technique enables the detec-
tion of original methylation states at specific CpG sites,
but it is difficult to design an adequate number of
unique probes to extend this approach to a genome-
wide scale. However, Hodges et al. [25] recently modi-
fied this strategy and integrated it with deep sequencing.
Table 1 Top 21 Gene Ontology categories between the YH and the mDC samples
Gene
name
GO ID NM GO category Methylation level
of mDC
Methylation level
of YH
P value
HELLS GO:0005524 NM_018063 ATP binding 33.333 1.316 4.54E-03
MSI1 GO:0007399 NM_002442 nervous system development 20.833 2.632 8.23E-03
CEBPE GO:0046983 NM_001805 protein dimerization activity 23.739 9.081 5.58E-79
EML2 GO:0007605 NM_012155 sensory perception of sound 27.621 13.554 9.63E-12
GLTSCR2 GO:0005634 NM_015710 nuclear 23.36 11.579 1.52E-04
TBC1D17 GO:0005096 NM_024682 GTPase activator activity 25.197 3.425 3.51E-14
BDH1 GO:0016491 NM_203314 oxidoreductase activity 22.892 11.345 6.49E-13
COL23A1 GO:0016021 NM_173465 integral to membrane 20.896 10.081 5.73E-03
WASF1 GO:0030041 NM_001024936 actin filament polymerization 22.215 10.467 9.32E-23
MYO1G GO:0016459 NM_033054 myosin complex 21.907 8.239 5.16E-13
ARMCX2 GO:0016021 NM_014782 integral to membrane 31.395 14.286 5.12E-04
MMP21 GO:0008270 NM_147191 zinc ion binding 9.375 33.862 1.05E-07
ITGA7 GO:0016020 NM_002206 membrane 10.879 21.88 1.39E-11
DHRS12 GO:0016491 NM_024705 oxidoreductase activity 8.696 23.144 1.55E-05
AURKC GO:0016740 NM_001015878 transferase activity 10.256 30.769 9.17E-03
SOX18 GO:0006357 NM_018419 regulation of transcription from RNA polymerase
II promoter
3.656 20.225 2.55E-15
CIDEC GO:0006917 NM_022094 induction of apoptosis 8.333 20.098 6.22E-04
PF4 GO:0045653 NM_002619 negative regulation of megakaryocyte
differentiation
0 22.222 3.13E-03
MARCKS GO:0051015 NM_002356 actin filament binding 5.405 30.088 4.66E-03
PRAF2 GO:0016021 NM_007213 integral to membrane 8.333 26.02 3.00E-03
FAM155B GO:0016021 NM_015686 integral to membrane 0 21.053 4.02E-04
The methylation level represents the average methylation level of the CpGs in the region. The P value was calculated using the chi-square test.
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Page 5 of 10For each CpG island, they designed two sets of probes;
one designed to detect no conversion at any of the CpG
residues and another to distinguish the full conversion
of CpGs to TpGs. They hypothesized that even with
completely random CpG methylation patterns, only half
of the CpG sites within a given probe would contribute
a mismatch, and that was tolerated. However, the
methods that were based on microarray hybridization
enrichment were either laborious or required large
volumes of DNA and were therefore not easily adapted
to the massive screening of clinical samples. In the cur-
rent study, we described a novel technique that com-
bined sequence capture with bisulfite conversion and
deep sequencing. In contrast to the strategy that Hodges
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Figure 4 Comparison of methylation levels between LHC-BS and BS-PCR. The top of the figure represents the methylation levels of CpGs in
the YH blood and mDC samples that were detected by LHC-BS. The height of the red box represents the methylation level of a CpG site. Each
rectangle underneath represents the methylation status of a CG in a fragment that was detected by BS-PCR. Red represents a methylated CpG
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DSPP gene and two highly methylated regions of the WDR37 (c) and DIP2B (d) genes using either HLC-BS or BS-PCR.
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probes without bisulfite conversion to capture native
genomic regions of interest. This adjustment in the
experimental procedures allowed for a drastic decrease
in the amount of DNA that was required for capture
and more accurate measurements of methylation sta-
tuses. Previously, Hodges et al. used 20 μgo fP C R -
amplified genomic DNA for a microarray-based capture
experiment. In contrast, 2-3 μg of genomic DNA was
used in the library construction for the present study,
and 500 ng of the constructed library was sufficient for
the hybridization capture and subsequent bisulfite treat-
ment. To protect the captured library, 200 ng of sheared
lDNA was added to act as carriers of the DNA that had
been eluted from the liquid capture in the current bisul-
fite treatment process. Based on these modifications, we
were not only able to facilitate the probe design process
by not requiring any prior consideration of methylation
sites but were also able to utilize small amounts of
native, unamplified input DNA to examine the methyla-
tion statuses of specific regions by designing probes that
covered different genomic regions.
Recent investigations involving DNA methylation
within different gene regions showed that exons are dis-
proportionately enriched in densely methylated genomic
elements [21,26-29]. Hypermethylation that occurs
downstream of the TSS and first exon is closely asso-
ciated with transcriptional silencing, whereas methyla-
tion that occurs in the more downstream portions of
the gene body is not [26,29]. In highly expressed genes,
the promoter regions are hypomethylated while the rest
of the gene-body regions are considerably methylated.
However, weakly expressed genes are moderately methy-
lated in both the promoter and gene-body regions.
Thus, the function of intragenic DNA methylation is
ambiguous. Previous research has indicated that intra-
genic DNA methylation, exonic nucleosomes and his-
tone modifications may function together to regulate
transcript splicing and gene expression [23,30,31].
Here, we profiled the human whole exome methyla-
tion statuses of two samples and obtained the same pat-
t e r n sa sw e r ep r e v i o u s l yd e t e c t e du s i n gW G B S[ 2 6 ] .
Using this set of probes, we covered 31% of the promo-
ter regions and approximately 100% of the exons. Most
of the regions that were not covered (Figure 2a) were
distributed in chromosomes 6 and Y. Because we only
calculated uniquely mapped reads, we determined that a
large number of multiple mapping were present in the
uncovered regions of chromosomes 6 and Y. For this
reason, the data that was obtained using LHC-BS did
not provide accurate methylation information for these
regions (Additional File 1 Table S4). Additionally, to
collect sufficient information, we generated massive
amounts of data using excessive sequencing depths for
the two samples, which reasonably led to the high dupli-
cation rate of 40.32% for the YH blood sample and
61.04% for the mDC cells. However, this value can be
adjusted by reducing the amount of raw sequencing
data in future studies. It has been reported that bisulfite
conversion may result in allele dropouts at low DNA
concentrations [32]. We calculated the allele loss rate to
be 2.5%, indicating efficient allele enrichment.
We applied a commercially available liquid hybridiza-
tion system for exon capture, for which all of the probes
were designed using the Watson strand of the human
genome. Therefore, only information regarding the
methylation of the Crick strand was obtained in this
study. However, DNA methylation occurs primarily at
CpG dinucleotides in mammalian genomes [1,2,33]. For
each round of DNA replication, DNMT1 DNA methyl-
transferase, which has a preference for hemimethylated
DNA, fills in the missing methylation sites on the newly
synthesized strand [34-36]. Thus, the presence of sym-
metric CpG methylation was presumed for the two
DNA strands composing each human chromosome. For
non-CpG methylation, which plays an important role in
maintaining the pluripotency of stem cells [11], we may
design probes in future studies that cover the double-
stranded regions of interest.
Conclusions
In the present study, we applied a liquid hybridisation
capture system to enrich for specific genomic regions,
which was combined with bisulfite sequencing to exam-
ine the methylation statuses of the human exome for
the first time. Two different samples were profiled, and
the methylation patterns of the exons were compared
with methylation patterns that had been obtained using
WGBS. These comparisons demonstrated the high accu-
racy of methylation estimation that is possible using this
novel LHC-BS method. In contrast with the array-based
capture strategy [25], we captured target regions without
pre-converting genomic DNA using a bisulfite treat-
ment. Instead, we used 2-3 μg of genomic DNA to con-
struct a library and 500 ng of them was then subjected
to target regions capture and a following bisulfite treat-
ment. This modification improved the efficacy of this
platform for methylation profiling, especially with regard
to its cost-effective use in the analysis of multiple clini-
cal samples for biomarker detection.
Methods
Sample preparation and DNA library construction
Two types of genomic DNA were isolated from a per-
ipheral blood sample that was obtained from the same
individual whose genome and methylome had been pre-
viously sequenced (YH) [26,37] and from a mature
human dendritic cell line (mDC). The total DNA from
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Page 7 of 10the peripheral blood sample was prepared using the
QIAamp DNA Blood Mini Kit following the manufac-
turer’s instructions, and the DNA from the mature
human dendritic cells was isolated by proteinase K
digestion and phenol/chloroform extraction.
Prior to the library construction, 2-3 μgo fg e n o m i c
DNA from each sample was fragmented using a Covar-
ias sonication system to mean sizes of approximately
200 bp. After fragmentation, libraries were constructed
according to the Illumina Paired-End protocol. Briefly,
the purified, randomly fragmented DNA was treated
with a mix of T4 DNA polymerase, Klenow fragments,
T4 polynucleotide kinase and a nucleotide triphosphate
mix to repair the ends by blunting and phosphorylation.
The blunted DNA fragments were subsequently 3’-ade-
nylated using the Klenow fragment (3’-5’ exo-) and
ligated by T4 DNA ligase to BGI-designed PE Index
Adaptors that had been synthesized with 5’-methylcyto-
sine in place of cytosine. After each step, the DNA was
purified using the QIAquick PCR Purification Kit (Qia-
gen). The constructed libraries were stored at -20°C
until the next step of hybridization.
Liquid hybridization-based exon capture
The SureSelect Human All Exon 38 Mb Kit was used
for the hybridization process. The probes nearly covered
all of the exons that were annotated by the CCDS in
September of 2008. The constructed libraries for the
capture were quantified using the Quant-iT dsDNA HS
Assay Kit with the Invitrogen Qubit fluorometer. Five
hundred nanograms of each library at concentrations of
147 ng/μl were required for the hybridizations as
described in the protocol for the SureSelect Target
Enrichment System for an Illumina Paired-End Sequen-
cing Library. The hybridizations were performed using a
thermal cycler that was set at 65°C for 24 hours with
the lid heated to 105°C; then, Dynabeads
® M-280 Strep-
tavidin (Invitrogen) was used to capture the biotinylated
RNA probes that had hybridized with the fragments of
the target regions. Finally, the captured library samples
were washed and purified for the bisulfite conversion.
Bisulfite conversion and PCR amplification
The bisulfite conversion of the captured exon DNA was
performed according to the instructions for the ZYMO
EZ DNA Methylation-Gold Kit™ with some modifica-
tions. A total of 200 ng of fragmented lDNA were
added to act as carriers for the elution products from
the hybridization. After the samples were denatured and
treated with sodium bisulfite, they were desulfonated,
and the cytosine was converted to uracil. PCR was car-
ried out in a final reaction volume of 50 μl that included
10 μl eluted bisulfite conversion products, 4 μl2 . 5m M
dNTP, 5 μl 10× buffer, 0.5 μl JumpStart™ Taq DNA
Polymerase, 2 μl PCR primers and 28.5 μlw a t e r .T h e
thermal cycling program was as follows: 94°C for 1 min,
18 cycles of 94°C for 10 s, 58°C for 30 s, 72°C for 30 s
and a final 5 min incubation at 72°C. The temperature
w a sh e l da t1 2 ° Cf o l l o w i n gthe termination of the
cycling program. PCR products that ranged in size from
200 to 400 bp were selected and gel purified using the
QIAquick Gel Extraction Kit (Qiagen). They were then
analyzed by the Bioanalyser Analysis System (Agilent,
Santa Clara, USA) and quantified using real time PCR.
According to the real time PCR measurements, two
PCR products of distinct samples were pooled on one
lane and sequenced by the Illumina Hiseq2000 using 90
bp paired-end sequencing reads.
Bisulfite sequencing of specific regions
Specific regions of bisulfite-treated genomic DNA from
each of the samples were PCR amplified, and the pro-
ducts were cloned and sequenced using conventional
Sanger sequencing. Briefly, 500 ng of genomic DNA
from each sample were converted according to the
ZYMO EZ DNA Methylation-Gold Kit™ manufacturer’s
instructions. PCR primers were designed using the
online MethPrimer software http://www.urogene.org/
methprimer/index.html. The PCR primer information is
listed in Additional File 1 Table S5. These primers were
designed to recognize regions that lack CpG sites to
avoid any amplification bias that may have occurred due
to the differences between the methylated and unmethy-
lated sequences. Thermal cycling was performed as fol-
lows: 94°C for 1 min, 30 cycles of 94°C for 10 s, 58°C
for 30 s, 72°C for 30 s and a final 5 min incubation at
72°C. The temperature was held at 12°C following the
termination of the cycling program. The PCR products
were purified using the QIAquick Gel Extraction Kit
(Qiagen). The purified PCR products were subcloned,
and colonies from each region were sequenced using
the 3730 Genetic Analyzer (Applied Biosystems) to
assess the methylated cytosine levels.
Bioinformatic analysis
The captured fragments were sequenced using an Illu-
mina Hiseq2000 sequencer that generated raw data in a
90 bp paired-end Fastq format. The data were processed
using the Illumina base-calling pipeline. Subsequently,
all reads were aligned to the hg18 reference genome
using the SOAP2.01 aligner [38]. Briefly, we used the
human reference genome to derive the soap libraries for
the assessment of the mapping results of the bisulfite
treatment. In the mapping process, the seed of a read
was 30 bp, and 2 mismatches were permitted. Only mis-
matches of 5 bp were allowed in the total read. Methyl-
cytosines were identified according to a previously
published strategy [26]. To reduce any bias that resulted
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Page 8 of 10from the PCR amplification, we chose optimal reads that
possessed fewer gaps and mismatches when more than
one read was mapped to the same position. Additionally,
we preferred the paired-end mapped reads. Methylation
levels were calculated using the following formula for
certain cytosine types: mC reads/(C reads +mC reads)
*100%. Because not all of the unmethylated cytosines
could be converted to uracils by the bisulfite treatment,
we estimated the non-conversion rate using the methy-
lation rate of non-CpG sites.
To validate the results of the LHC-BS, Pearson’sc o r -
relation analysis were utilized to conduct pair-wise com-
parisons between datasets that were derived from the
LHC-BS and WGBS assays. For the BS-PCR validation
analysis, the BLAST algorithm was applied to align the
sequences (expect value = 1E-10). The Fisher’s test was
used to statistically define the significances of the differ-
ences between the methylation information that was
generated by LHC-BS and BS-PCR (P value < 0.01).
Three parameters were applied to identify the differ-
entially methylated regions between the mDC cell line
and YH blood sample. First, we summed all of the
methylated and unmethylated nucleotides in the CpG
sites for each region of the two samples, respectively.
The Fisher’s test was used to analyze the methylation
differences for each target region using a P value < 0.01.
Second, we separated out the regions that showed over
two-fold increases in methylation levels between sam-
ples. Third, considering the non-uniformity of the
methylation levels, we selected regions with differences
in methylation of over 20% between the two samples.
The obtained differentially methylated regions were then
examined using the BGI WEGO software to determine
the functional information for their respective genes.
Additional material
Additional file 1: Supplementary Tables 1-5. Table S1: Data statistics
of YH and mDC from HLC-BS. Table S2: Assessment of the dropout of
alleles of heterozygous genes from the YH LHC-BS data. Table S3:
Statistics of the methylation statuses of 27 individual CpG sites that were
analyzed by HLC-BS and BS-PCR. P values were calculated using the chi-
square or Fisher’s tests. Table S4: Analysis of the undetected target
region characteristics. Table S5: BS-PCR primer information.
Additional file 2: Figure S1 LHC-BS read distribution along
chromosome 12.
Additional file 3: Figure S2 Comparison of methylation rates
between WGBS and LHC-BS. (a) The Pearson’s correlation coefficient
from the YH blood sample was 0.907, and the confidence interval was
0.902-0.912; (b) for the mDC cell line, the correlation coefficient was
0.925, and the confidence interval was 0.921-0.928. The y-axis shows the
methylation rate of a cytosine as determined by the whole genome
sequencing of bisulfite-treated DNA, and the x-axis shows the
methylation level as determined by HLC-BS. This analysis was restricted
to cytosines with at least nine reads in both samples.
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